Related Experiment Videos
Regulation of chemokine expression in atherosclerosis
Anne Burke-Gaffney1, Alison V S Brooks, Richard G Bogle
1Unit of Critical Care, National Heart and Lung Institute Division, Imperial College of Science, Technology and Medicine, Dovehouse Street, London SW3 6LY, UK. a.burke-gaffney@ic.ac.uk
Insights
Chemokines are key drivers of atherosclerosis, promoting inflammation and plaque development. Understanding chemokine release mechanisms is vital for developing effective atherosclerosis treatments.
Area of Science:
- Cardiovascular Biology
- Immunology
- Molecular Medicine
Background:
- Chemokines are central to atherosclerosis pathogenesis, driving leukocyte recruitment, angiogenesis, and smooth muscle cell proliferation.
- Leukocytes and endothelial cells are significant chemokine sources, with atherosclerosis risk factors exacerbating chemokine expression.
- Cellular interactions amplify chemokine release, potentially sustaining generation in inflammatory atherosclerotic conditions.
Purpose of the Study:
- To summarize current knowledge on chemokine release in atherosclerosis.
- To discuss how pharmacological strategies targeting chemokine release contribute to atherosclerosis treatment.
- To highlight the importance of understanding chemokine expression mechanisms for therapeutic development.
Main Methods:
- Literature review and synthesis of existing research on chemokines in atherosclerosis.
- Analysis of pharmacological interventions that inhibit chemokine release.
- Discussion of the mechanisms controlling chemokine expression.
Main Results:
- Chemokines significantly contribute to leukocyte recruitment, angiogenesis, and smooth muscle cell migration in atherosclerotic plaques.
- Atherosclerosis risk factors and cell-cell interactions enhance chemokine expression and sustained release.
- Several therapeutic strategies for atherosclerosis target and inhibit chemokine release.
Conclusions:
- Chemokine-mediated processes are critical in atherosclerosis development.
- Inhibition of chemokine release is a potential therapeutic avenue for atherosclerosis.
- Further understanding of chemokine regulation is essential for novel anti-atherosclerosis drug design.
Abstract:
(1) Chemokines play a central role in the pathogenesis of atherosclerosis, contributing to leukocyte recruitment, angiogenesis and also proliferation and migration of smooth muscle cells into atherosclerotic plaques. (2) Leukocytes and endothelial cells are an important source of chemokines, and many of the risk factors associated with atherosclerosis increase chemokine expression. There is now a body of evidence to suggest that interactions between cells such as leukocytes and endothelial cells amplify chemokine release, and this may contribute to sustained chemokine generation in inflammatory conditions. (3) This article summarises, briefly, what is currently known about chemokines release. A number of important pharmacological strategies used in the treatment of atherosclerosis inhibit chemokine release and the extent to which this may contribute to their therapeutic effect will be discussed. Understanding the mechanisms controlling chemokine expression is essential for the design of specific therapeutic interventions in atherosclerosis.